Physician profile
Derek Heimlich
NPI 1699393090
$3,476.52
in general payments reported to CMS, 2019-2025
26 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $124 · 2021: $62.93 · 2022: $376 · 2023: $692 · 2024: $1,093 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,851 · Education: $63.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,850.50 |
| Education | $63.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.05 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $387.58 | 2023-2025 | Syfovre |
| Bausch & Lomb Americas INC. | $356.28 | 2022-2025 | Miebo, Infuse, Xiidra |
| Tarsus Pharmaceuticals, INC. | $354.26 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $287.19 | 2022-2025 | Tryptyr, Eysuvis, Clareon |
| Regeneron Healthcare Solutions, INC. | $210.61 | 2023-2024 | Eylea Hd, Eylea |
| Oyster Point Pharma, INC. | $187.20 | 2022-2025 | Tyrvaya, Ryzumvi |
| Aerie Pharmaceuticals, INC. | $123.74 | 2020 | |
| Alimera Sciences, INC. | $122.57 | 2022-2024 | Iluvien, Yutiq |
| Biotissue Holdings INC. | $119.74 | 2022-2024 | |
| Genentech USA, INC. | $112.46 | 2024-2025 | Vabysmo, Susvimo |
| Allergan, INC. | $107.53 | 2022 | |
| Harrow Eye, LLC | $106.41 | 2024-2025 | Vevye |
| Dompe US, INC. | $91.00 | 2024 | Oxervate |
| Astellas Pharma US INC | $87.71 | 2023-2025 | Izervay |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $64.48 | 2022-2023 | |
| Ivantis, INC | $62.93 | 2021 | |
| Sun Pharmaceutical Industries INC. | $49.29 | 2022-2025 | |
| Amgen INC. | $30.07 | 2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $29.90 | 2024 | Acthar |
| Thea Pharma INC. | $25.77 | 2023 | Iyuzeh |
| Coherus Oncology, INC. | $21.11 | 2023 | |
| Ani Pharmaceuticals, INC. | $20.97 | 2025 | Purified Cortrophin Gel |
| Glaukos Corporation | $20.97 | 2024 | Istent Trabecular Micro-Bypass System Model Is3 |
| Eyepoint US, INC. | $17.43 | 2022 | |
| Horizon Therapeutics Plc | $17.27 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Heimlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.